Insider · CIK 0001622251
Paul Goode
Files at GCTK (Glucotrack, Inc.). First filing -, latest -.
In brief
Paul Goode files SEC Form 4 as CEO and director at GCTK (Glucotrack, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Paul Goode has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 25, 2025 | GCTK Glucotrack, Inc. | JOther Common Stock, par value $0.001 per share | +42 | - | - | 339 | Oct 7, 2025 |
| Nov 14, 2024 | GCTK Glucotrack, Inc. | CConversion Common Stock, par value $0.001 per share | +796 | $31.20 | $25k | 2,054 | Mar 28, 2025 |
| Feb 5, 2025 | GCTK Glucotrack, Inc. | JOther Common Stock, par value $0.001 per share | +1,500 | - | - | 3,554 | Mar 28, 2025 |
| Mar 12, 2025 | GCTK Glucotrack, Inc. | XIn-the-money exercise Common Stock, par value $0.001 per share | +15,435 | $0.00 | $0 | 18,989 | Mar 28, 2025 |
| Jun 14, 2024 | GCTK Glucotrack, Inc. | AGrant or award Stock option (right to buy)derivative | +3,277 | $0.00 | $0 | 3,277 | Mar 28, 2025 |
| Jul 1, 2024 | GCTK Glucotrack, Inc. | POpen-market purchase Warrants to Purchase Common Stockderivative | +2,100 | - | - | 2,100 | Mar 28, 2025 |
| Jul 18, 2024 | GCTK Glucotrack, Inc. | POpen-market purchase Convertible Promissory Notederivative | - | $10,000.00 | - | - | Mar 28, 2025 |
| Nov 14, 2024 | GCTK Glucotrack, Inc. | CConversion Convertible Promissory Notederivative | - | $24,831.00 | - | - | Mar 28, 2025 |
| Nov 14, 2024 | GCTK Glucotrack, Inc. | AGrant or award Series A Common Warrantderivative | +796 | - | - | 796 | Mar 28, 2025 |
| Nov 14, 2024 | GCTK Glucotrack, Inc. | AGrant or award Series B Common Warrantderivative | +796 | - | - | 796 | Mar 28, 2025 |
| Mar 12, 2025 | GCTK Glucotrack, Inc. | XIn-the-money exercise Series B Common Warrantderivative | +796 | $0.00 | $0 | 0 | Mar 28, 2025 |
Questions about Paul Goode
Answered from the filings on this page, as of the latest one.
Is Paul Goode buying or selling?
Paul Goode has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Paul Goode's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Paul Goode has 0.
Where does Paul Goode file Form 4?
Paul Goode has filed Form 4 at GCTK (Glucotrack, Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.